Regulation of CTLs/Tregs via Highly Stable and Ultrasound‐Responsive Cerasomal Nano‐Modulators for Enhanced Colorectal Cancer Immunotherapy
Open Access
- 29 March 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (22) , e2400485
Abstract
Immunotherapy is showing good potential for colorectal cancer therapy, however, low responsive rates and severe immune‐related drug side effects still hamper its therapeutic effectiveness. Herein, a highly stable cerasomal nano‐modulator (DMC@P‐Cs) with ultrasound (US)‐controlled drug delivery capability for selective sonodynamic‐immunotherapy is fabricated. DMC@P‐Cs’ lipid bilayer is self‐assembled from cerasome‐forming lipid (CFL), pyrophaeophorbid conjugated lipid (PL), and phospholipids containing unsaturated chemical bonds (DOPC), resulting in US‐responsive lipid shell. Demethylcantharidin (DMC) as an immunotherapy adjuvant is loaded in the hydrophilic core of DMC@P‐Cs. With US irradiation, reactive oxygen species (ROS) can be effectively generated from DMC@P‐Cs, which can not only kill tumor cells for inducing immunogenic cell death (ICD), but also oxidize unsaturated phospholipids‐DOPC to change the permeability of the lipid bilayers and facilitate controlled release of DMC, thus resulting in down‐regulation of regulatory T cells (Tregs) and amplification of anti‐tumor immune responses. After intravenous injection, DMC@P‐Cs can efficiently accumulate at the tumor site, and local US treatment resulted in 94.73% tumor inhibition rate. In addition, there is no detectable systemic toxicity. Therefore, this study provides a highly stable and US‐controllable smart delivery system to achieve synergistical sonodynamic‐immunotherapy for enhanced colorectal cancer therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82071941, 32271443, 81871363, 82272019, 82000509)
- Peking University Third Hospital (BYSYZD2019018, jyzc2018‐02, BYSY2015023)
- Natural Science Foundation of Beijing Municipality (JQ22024, L232087)
This publication has 48 references indexed in Scilit:
- Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapyBioactive Materials, 2022
- Engineering oxygen-deficient ZrO2-x nanoplatform as therapy-activated “immunogenic cell death (ICD)” inducer to synergize photothermal-augmented sonodynamic tumor elimination in NIR-II biological windowBiomaterials, 2021
- Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung MetastasisAdvanced Materials, 2021
- Molecular-level effects on cell membrane models to explain the phototoxicity of gold shell-isolated nanoparticles to cancer cellsColloids and Surfaces B: Biointerfaces, 2020
- Redox responsive liposomal nanohybrid cerasomes for intracellular drug deliveryColloids and Surfaces B: Biointerfaces, 2016
- Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriersAdvances in Colloid and Interface Science, 2014
- Co‐Delivery of Oxaliplatin and Demethylcantharidin via a Polymer–Drug ConjugateMacromolecular Bioscience, 2013
- Design and Synthesis of Lipidic Organoalkoxysilanes for the Self‐Assembly of Liposomal Nanohybrid Cerasomes with Controlled Drug Release PropertiesChemistry – A European Journal, 2013
- Hyperthermia and Thermosensitive Liposomes for Improved Delivery of Chemotherapeutic Drugs to Solid TumorsPharmaceutical Research, 2010
- Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cellsEuropean Journal of Cancer, 1995